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Abstract
Background: This paper reports on the availability of diagnostic tools and recommended anti-malarials in the
12-month period immediately following the implementation of a new national malaria treatment protocol (NMTP)
in Papua New Guinea (PNG). Health worker adherence to the new NMTP is also examined and comparisons made
with previously reported pre-implementation findings.
Methods: A countrywide cross-sectional survey in randomly selected primary health care facilities (n = 88). Data
were collected via passive observation of the clinical case management of fever or suspected malaria patients and
via an interviewer administered questionnaire completed with the officer in charge of each participating health
care facility.
Results: Malaria rapid diagnostic tests (RDTs) and the new first-line anti-malarial medication, artemether-
lumefantrine (AL), were available in 53.4% and 51.1% of surveyed heath facilities, respectively. However, they were
more widely available in the larger health centres as compared to the smaller aid-posts (90.2% vs. 21.3% and 87.8%
vs. 19.2%, respectively). Overall, 68.3% of observed fever cases (n= 445) were tested for malaria by RDT and 39%
prescribed an anti-malarial, inclusive of 98.2% of RDT positive patients and 19.8% of RDT negative cases. The availability
and use of malaria RDTs was greater in the current survey as compared to pre-implementation of the new NMTP
(8.9% vs. 53.4% & 16.2% vs. 68.3%, respectively) as was the availability of AL (0% vs. 51.1%). The percentage of fever
patients prescribed anti-malarials decreased substantially post implementation of the new NMTP (96.4% vs. 39.0%).
Conclusions: PNG has achieved high coverage of malaria RDTs and AL at the health centre level, but these resources
have yet to reach the majority of aid-posts. Malaria case management practice has substantially changed in the
12-month period immediately following the new NMTP, although full protocol adherence was rarely observed.
Background
Papua New Guinea (PNG), a malaria-endemic country
of approximately seven million people in the South
Pacific, introduced a new national malaria treatment
protocol (NMTP) in late 2011. Consistent with the rec-
ommendations of the World Health Organization [1],
the new NMTP stipulates that all fever or suspected
malaria cases be tested for malaria infection by mi-
croscopy or rapid diagnostic test (RDT), introduces
artemether-lumefantrine (AL) as the new first-line treat-
ment for uncomplicated Plasmodium falciparum ma-
laria, AL plus primaquine (PQ) as the new first-line
treatment for uncomplicated Plasmodium vivax malaria
and artesunate injection followed by AL for first-line
treatment of severe P. falciparum malaria, with the
addition of PQ for the treatment of severe P. vivax
malaria [2]. Dihydroartemisinin-piperaquine was also in-
troduced as the new second-line treatment for uncom-
plicated P. falciparum and P. vivax malaria, with the
addition of PQ for the latter.
A national cross-sectional survey conducted prior to
the implementation of the new NMTP identified malaria
RDTs or functional microscopy in only 15% of health fa-
cilities [3]. The lack of diagnostic capacity was evident in
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of 468 observed fever cases tested for malaria infection
by microscopy or RDT [4], although this rose to 40.9%
when the analysis was restricted to fever cases managed
in health facilities with access to malaria RDTs or func-
tional microscopy. Anti-malarial prescription was near
universal with 96.4% of the 468 observed fever cases pre-
scribed an anti-malarial, including 82% of the 50 patients
who tested negative for malaria infection by microscopy
or RDT [4]. Overall, 79.8% of these prescriptions con-
formed to the treatment protocol current at that time.
These baseline findings indicate a substantial change
in malaria diagnostic capacity and malaria case manage-
ment practice will be required if the new NMTP is to be
successfully implemented in PNG. In particular, access
to malaria RDTs or functional microscopy will need to
improve and health workers will need to utilize malaria
RDTs or microscopy at greater rates when they are avail-
able. As recent evidence indicates that many fever cases
presenting to health facilities in PNG are non-malarial
in origin [5], then adherence to the new protocol will
likely see rates of anti-malarial prescription reduce dra-
matically e.g. [6]. The international experience suggests
these changes in health worker practice will take some
time to achieve. For example, three years after the im-
plementation of a protocol stipulating routine micros-
copy or RDT testing of all adult fever cases and the
prescription of AL to test positive cases in Kenya, testing
rates in health facilities with RDT or microscopy avai-
lable did not exceed 54% and nearly a third of test ne-
gative cases were prescribed AL [7]. Similar accounts of
poor health worker adherence and other institutional
barriers to the implementation of an RDT/artemisinin
combination therapy-based malaria treatment policy
have been documented elsewhere [8,9], including neigh-
bouring Timor-Leste [10].
In order to assess implementation progress in PNG,
this paper reports on the availability of microscopy, mal-
aria RDT, AL and other recommended anti-malarials in
the 12-month period immediately following introduction
of the new NMTP, as well as health worker adherence to
the recommended diagnostic and prescription practices.
Comparisons in resource availability and malaria case
management practice are made with previously reported
pre-implementation findings.
Methods
Study setting
PNG is thought to have one of the highest burdens of
malaria outside of Africa. A countrywide household sur-
vey conducted in 2008/2009 reported general population
malaria prevalence of 18.2% [11] with the National De-
partment of Health reporting 1,431,395 suspected ma-
laria cases and 604 malaria attributable deaths in 2009
[12]. A 2008 study of 1807 febrile patients presenting to
five sentinel health facilities across PNG reported a mal-
aria slide positivity rate of 45.4% [5], although marked
variation ranging from 2.2% to 74.9% across sites was
observed. However, more recent evidence indicates a de-
creasing malaria burden. Following two rounds of free
countrywide distributions of long lasting insecticidal
mosquito nets, general population prevalence of malaria
had reduced to 6.7% in 2011 [11] and a 50% reduction
in clinical incidence between was reported in East Sepik
province [13].
Study procedures
The study procedures for the health facility survey re-
ported in this paper are consistent with a 2010 survey
previously described [3,4]. A detailed description of
the evaluation of the PNG National Malaria Control
Programme, of which the health facility surveys are
one of several components, is also available in the
published literature [14]. The following description of
the survey methodology is a summarized version of
these previously published accounts.
At the time of drafting the health facility survey me-
thodology, PNG consisted of 20 provinces divided into
four geographical regions (Southern, Highlands, Momase,
and Islands). The study sample consisted of two health
centres or health subcentres (collectively referred to as
health centres in this paper) and up to four aid posts se-
lected from each of these 20 provinces, using a simple
random sampling procedure. The sampling frame was a
list of all operational public-sector health centres nation-
wide as provided by the National Department of Health
(N=689; the small number of private sector health facil-
ities were excluded from survey). Aid posts were randomly
selected on site at participating (i e, randomly selected and
consenting) health centres. The sampling frame for aid
posts was all operational aid posts under the supervision
of the health centre at the time of survey.
The study was carried out from June to November
2012 and was conducted by three trained field teams
working simultaneously at different sites. Members of
each survey team spent between three to five days at
each participating health centre and up to one day at
each participating aid post. Four survey instruments
were completed at each health facility, although this
paper only reports data obtained from two of these: a
structured checklist completed with the officer in charge
of the participating health facilities, designed to assess
the availability of supplies relevant to malaria case man-
agement; and, a structured checklist designed to record
observed features of the clinical case management of pa-
tients presenting with fever or a recent history of fever.
The remaining instruments included interviewer admi-
nistered questionnaires completed with health workers
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formation obtained from these questionnaires primarily
centered on barriers to (health worker interviews), and
the quality of (patient interviews), service provision and
will be reported separately. Oral informed consent was
sought from the officer in charge at all participating
health facilities and from all participating clinicians and
patients prior to clinical observation. The study was ap-
proved and granted ethical clearance by the Medical Re-
search Advisory Committee of PNG (MRAC No. 10.12;
26 Feb 2010).
Data analysis
All data were double entered into DMSys version 5.1
(Sigma Soft International). Stata/SE version 12 was used
for descriptive data analysis, for calculating 95% confi-
dence intervals (CIs) and for comparing differences in
malaria resource availability and malaria case management
between health facility types and/or pre- and post-NMTP
implementation (Pearson chi square). A complete descrip-
tion of pre-NMTP implementation data can be found
elsewhere [3,4]. The calculation of all CIs reported on the
non-participant observation sample was adjusted for pos-
sible clustering at the health facility level by using the
Stata ‘svy’ command in which health facilities were defined
as the primary sampling unit.
Results
Resource availability
A total of 88 health facilities were included in the survey.
Of these, 41 were health centres and 47 were aid posts
(Table 1).
The availability of diagnostic tools and medications ne-
cessary for implementation of the revised NMTP is pre-
sented in Table 2. As shown, RDTs were more widely
available than microscopy and the small number of
health facilities that had functional microscopy available,
also had RDTs in stock. An additional seven health facil-
ities had a microscope in stock, but did not meet the
study definition of functional microscopy: the presence
of a working microscope, all essential supplies (Giemsa
stain, slides and, in the case of electric microscopes,
power) and a trained microscopist in employment.
The brand of RDT kit was recorded in 35 health facil-
ities, the majority of which had the ICT malaria combo
test (n= 33). CareStart™ Malaria brand RDTs was present
in one health facility and both ICT and CareStart™ in a
further health facility. Resource availability was substan-
tially greater at the health centre level as compared to
the aid post level in nearly all cases. The difference in
availability of RDTs and AL, the two resources most
commonly required in the implementation of the new
protocol, between the health facility types, reached a level
of statistical significance (χ
2=41.857, p<0.001; χ
2=
41.309, p<0.001, respectively). Overall, a total of 27,777
unexpired RDT kits were observed across the health facil-
ity sample compared to a total of 53,677 unexpired AL
doses. Of the 47 health facilities with either AL or RDT in
stock, 80.9% (38/47) had more AL than RDT.
The availability of RDTs increased from 8.9 to 53.4%
(χ
2=37.7587, p <0.001) across all health facilities be-
tween 2010 (previously reported pre-implementation
survey) and 2012 and from 17.5 to 90.2% (χ
2= 43.1785,
p<0.001) and 0 to 21.3% (χ
2 =9.3897, p=0.002) at the
health centre and aid post levels, respectively. AL was
not available at any health facility in the 2010 survey.
Malaria case management
A total of 556 clinical observations were completed with
patients presenting with fever or a recent history of fever
during the survey period. Patients who had been treated
for fever or malaria infection within 14 days prior to
interview were subsequently removed from analysis to
ensure the findings better represented initial malaria
case management practice. This restriction resulted in a
final sample of 445 clinical observations obtained from
43 health facilities. Only 1.4% (6/445) of these patients
were treated at an aid post, an outcome which reflects
the brief amount of time the research teams spent at
aid-posts relative to health centres and the fact that a
single aid post receives fewer patients than a single
health centre (although aid posts are more numerous
than health centres so still account for a substantial
number of outpatient cases per year). Table 3 presents
sex and age characteristics of the observed fever patients
by region.
Use of RDT or microscopy
Overall, 68.3% (304/445; 95% CI 52.0, 81.1) of the ob-
served fever patients were tested for malaria infection by
RDT. When restricted to health facilities that had RDT
in stock, this increased to 73.3% (280/382; 95% CI 55.7,
85.7). A blood slide was not taken from any of the ob-
served fever patients. No statistically significant diffe-
rence was observed in the percentage of patients tested
for malaria infection by age (<five years vs five +years)
or sex (female vs male) in those health facilities with
RDT in stock (74.5 vs 72.4%; χ
2=0.2975, p =0.862 and
72.9 vs 73.8%; χ
2 =1.6505, p =0.438, respectively).
Table 1 Surveyed health facilities by type and region
Health facility
type
Region Total
Southern Highlands Momase Islands
Health centre 15 11 8 7 41
Aid post 16 11 10 10 47
Total 31 22 18 17 88
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agement increased by a statistically significant level
across all health facilities between 2010 and 2012 (16.2
vs 68.3% χ
2 =253.2963, p<0.001), including when the
analysis was restricted to only those health facilities
that had RDT or microscopy available (41.5 vs 73.3%,
χ
2 =43.6338, p< 0.001).
Anti-malarial prescription
Prescription information was available for 98.4% (438/445)
of the observed fever patient sample. Table 4 presents the
number and percentage of these patients prescribed an
anti-malarial (any anti-malarial and AL) by diagnostic ca-
tegory (no RDT, positive RDT result, negative RDT result)
and overall. As can be seen, 39% (171/438) of the observed
Table 2 Percentage of health facilities with the required resources for implementation of the new national malaria
treatment protocol
Resource Health centre Aid post Overall
% (95% CI) % (95% CI) % (95% CI)
Diagnostic Test
RDT 90.2 (76.9, 97.3) 21.3 (10.7, 35.7) 53.4 (42.5, 64.1)
Microscopy
a, 7.3 (1.5, 19.9) 2.1 (<0.1, 11.3) 4.6 (1.3, 11.2)
RDT or microscopy 90.2 (76.9, 97.3) 21.3 (10.7, 35.7) 53.4 (42.5, 64.1)
Recommended medication – first- and second-line treatment
b
AL
c, all categories 87.8 (73.8, 95.9) 19.2 (9.1, 33.3) 51.1 (40.2, 61.9)
AL, 5–15 kg 95.1 (83.5, 99.4) 21.3 (10.7, 35.7) 55.7 (44.7, 56.3)
AL, 15-25 kg 92.7 (80.1, 98.5) 23.4 (12.3, 38.0) 55.7 (44.7, 56.3)
AL, 25–35 kg 92.7 (80.1, 98.5) 19.2 (9.1, 33.3) 53.4 (42.5, 64.1)
AL, 35+ kg 92.7 (80.1, 98.5) 23.4 (12.3, 38.0) 55.7 (44.7, 56.3)
AL+ PQ
d 68.3 (51.9, 81.9) 14.9 (6.2, 28.3) 39.8 (29.5, 50.1)
DP
e 4.9 (<0.1, 16.5) 0 - 2.3 (<0.1, 8.0)
AI+AL
f 70.7 (54.5, 83.9) 8.5 (2.4, 20.4) 37.5 (27.4, 48.5)
AI+AL+PQ
g 61.0 (44.5, 75.8) 8.5 (2.4, 20.4) 33.0 (23.3, 43.8)
QI+ QT+DX
h 65.9 (49.4, 79.9) 29.8 (17.3, 44.9) 46.6 (35.9, 57.5)
Selected ‘other’ anti-malarial medication
SP 97.6 (87.1, 99.9) 87.2 (74.3, 95.2) 92.1 (84.3, 96.7)
CQ 92.7 (80.1, 98.5) 85.1 (71.7, 93.8) 88.6 (80.1, 94.4)
AQ 92.7 (80.1, 98.5) 87.2 (74.3, 95.2) 89.8 (81.5, 95.2)
Artemether tablets 68.3 (51.9, 81.9) 42.6 (28.3, 57.8) 54.6 (43.6, 65.2)
aMicroscopy was defined as the presence of a functional microscope, all essential supplies (Giemsa stain, slides and, in the case of electric microscopes, power)
and a trained microscopist in employment.
bThe quantity of each medication was not accounted for in this analysis; rather, the data represent the percentage of health facilities that had at least one vial or
container (inclusive of a single, opened container) of the respective anti-malarial in stock.
cFirst-line treatment for uncomplicated P. falciparum infection.
dFirst-lline treatment for uncomplicated P. vivax infection.
eSecond-line treatment for uncomplicated malaria infection.
fFirst-line treatment for severe P. falciparum infection.
gFirst-line treatment for severe P. vivax infection.
hSecond-line treatment for severe malaria infection.
AL= artemether-lumefantrine, PQ= primaquine, DP= dihydroartemisinin-piperaquine, AI = artemether or artesunate injection, QI = quinine injection, QT = quinine
tablets, DX = doxycycline, SP = sulphadoxine-pyrimethamine, CQ = chloroquine, AQ= amodiaquine.
Table 3 Sex and age of the clinical observation sample by region (n= 445)
Characteristic Region Overall
Southern Highlands Momase Islands
Female n (%) 70 (51.1) 54 (47.4) 67 (52.8) 48 (71.6) 239 (53.7)
Age n (%) 0–4 yrs 57 (41.6) 51 (44.7) 62 (48.8) 26 (38.8) 196 (44.0)
5–15 yrs 34 (24.8) 15 (13.2) 29 (22.8) 20 (29.9) 98 (22.0)
16+ yrs 46 (33.6) 48 (42.1) 36 (28.4) 21 (31.3) 151 (33.9)
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and 12.8% AL. Of the patients tested for malaria infection
by RDT, 98.2% of test positive cases were prescribed an
anti-malarial as were 19.4% of test negative cases. All
except one of the test positive cases prescribed an anti-
malarial were given AL compared to fewer than 1% of test
negative cases.
Of the 98.5% (53/54) RDT-positive patients who were
prescribed AL, 41.5% (22/53) tested positive for “P.
falciparum mono-infection or mixed infection”, 35.8%
(19/53) for “P. falciparum”, 17.0% (9/53) for “non-falcip-
arum” (P. vivax, P. ovale, P. malariae or a mixed infec-
tion of these) and in 5.7% (3/53) cases the species result
was not recorded. According to the NMTP, patients who
test positive for a mixed infection or a non-P. falciparum
infection should also be prescribed primaquine. This oc-
curred in 51.6% (16/31) of these cases. Chloroquine was
prescribed in addition to primaquine in one mixed infec-
tion case and primaquine was prescribed to one P. fal-
ciparum-infected patient. No other anti-malarials were
prescribed to these patients, although some form of
other medication was provided in 51.9% (28/54) of RDT-
positive cases. These other medications included analge-
sics (n =23), antibiotics (n =8), antihelminthics (n =7)
and anti-anaemia (n =2).
Of the RDT negative or presumptively diagnosed
patients prescribed anti-malarials, 75% (87/116) were
prescribed the obsolete first-line treatment for uncom-
plicated malaria (either amodiaquine and sulphadoxine/
pyrimethamine (SP) or chloroquine and SP). The re-
maining patients were prescribed amodiaquine (n =12),
artemether tablets and SP (n =5), quinine tablets and SP
(n =2), artemether tablets (n =2), SP (n= 2), AL (n = 2),
artesunate tablets and SP (n =1), chloroquine, SP and
primaquine (n = 1), artemether tablets, SP and prima-
quine (n =1) or chloroquine, SP and quinine (n = 1).
Overall, 84.5% (98/116) of these patients were observed
in a health facility which had all doses of AL in stock.
Some other form of medication was provided in 79.3%
(92/116) of cases. These other medications included
antibiotics (n =71), analgesics (n =65), antihelminthics
(n =14), antiprotozoals (n =2), anti-anaemia (n =2) and
gastro-intestinal medication (n =1). Patients prescribed
an anti-malarial either presumptively or with a negative
RDT result were more likely to be prescribed another
form of medication compared to RDT-positive patients
prescribed an anti-malarial (79.3 vs 51.9%; χ
2= 17.2258,
p<0.001).
In terms of compliance with the NMTP prescription
regimen, 19.3% (33/171) of the patients prescribed an
anti-malarial were prescribed the correct first-line medi-
cation for uncomplicated malaria infection (defined as a
prescription of AL to P. falciparum infection or AL and
primaquine to a potentially mixed or non-P. falciparum
infection). A further five patients (2.9%) were prescribed
AL presumptively, which may be considered a correct
prescription in the absence of an RDT or microscopy
result.
Anti-malarial prescription to any patient decreased by
a statistically significant level across all health facilities
between 2010 and 2012 (96.4 vs 39.0%; χ
2 =336.8467,
p<0.001). The prescription of anti-malarial medication
consistent with extant guidelines also decreased by a sta-
tistically significant margin across these two time periods
(79.8 vs 22.2%; χ
2=161.5372 p< 0.001), primarily as a re-
sult of the continued prescription of the former (obsolete)
first-line anti-malarials to RDT negative and presump-
tively diagnosed patients.
Treatment counselling
The percentage of fever patients observed to have been
provided with each of six different ‘types’ of clinical in-
struction by their respective clinician(s) is presented in
Table 5. The sample was restricted to patients who had
been prescribed anti-malarial medication. As shown, the
Table 4 Number and percentage of observed fever patients prescribed an anti-malarial by diagnostic category and
overall
Diagnostic category No (%) Any antimalarial Artemetherlumefantrine
% 95% CI % 95% CI
No RDT 136 (31) 51.5 (28.6, 73.8) 1.5 (<0.1, 11.4)
Positive RDT 54 (12) 98.2 (84.1, 99.8) 98.2 (84.1, 99.8)
Negative RDT 248 (57) 19.4 (9.6, 35.1) <1 (<0.1, 2.8)
Overall 438 (100) 39.0 (27.8, 51.7) 12.8 (7.4, 21.3)
Table 5 Observed provision of instructions to patients
prescribed anti-malarial medication (n= 171)
Instruction % provided (95% CI)
Purpose of medication 64.9 (57.3, 72.0)
Dosage/regimen 86.0 (74.8, 92.7)
Dietary 17.5 (10, 29)
Possible adverse effects 2.3 (0.6, 5.9)
Health facility re-engagement
a 18.1 (12.7, 24.7)
Prevention advice 19.3 (13.7, 26.0)
aIn which patients are advised to return to the health facility if current
symptoms persist or deteriorate.
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supplied were explained in the majority of cases (86 and
64.9%, respectively). The remaining instructions were all
provided in fewer than 25% of cases, with an explanation
of possible adverse effects discussed in 2.3% of cases.
When compared to the previously reported 2010 find-
ings, statistically significant increases in the percentage
of patients receiving the following forms of clinical
instruction were evident: dosing regimen (75.7 vs 86%;
χ
2= 8.2609, p=0.004); dietary advice (6.2 vs 17.5%;
χ
2= 19.4929, p<0.001); and malaria prevention advice
(10.3 vs 19.3%; χ
2=9.2663, p= 0.002). A statistically sig-
nificant decrease in the percentage of patients receiving
instruction on when to return to the health facility was
observed (27.7 vs 18.1%; χ
2 =4.9317, p=0.026). Changes
in the percentage of patients receiving the remaining
instructions did not reach a level of statistical signifi-
cance: purpose of medication (63.4 vs 64.9%; χ
2=0.7739,
p=0.379) and explanation of possible side effects/adverse
events (1.1 vs 2.3%; χ
2=1.1796, p=0.277).
Discussion
The reported findings indicate that RDTs are widely
available at the health centre level of service provision in
PNG as are all four weight packs of AL (90.2 and 87.8%
of surveyed health centres, respectively). These diagnos-
tic and treatment resources were available in fewer than
20% of health centres prior to the introduction of the
new NMTP [3], indicating widespread coverage has been
achieved in a relatively brief period of time. However,
other anti-malarial medications required in the new
NMTP, such as primaquine, artesunate and particularly
dihydroartemisinin-piperaquine, were less available; the
available quantity of RDTs relative to AL dosages ap-
peared insufficient and the availability of all recom-
mended diagnostic tools and anti-malarial medications
remained low at the aid post level. Thus, the vast major-
ity of health centres were adequately equipped to treat
uncomplicated P. falciparum infection according to the
new NMTP, but were less well equipped to treat uncom-
plicated P. vivax infections, severe malaria infections or
to provide second-line treatments. Fewer than 20% of
aid posts were equipped to treat any form of malaria in-
fection in a manner consistent with the new NMTP. As
aid posts comprise more than 70% of all heath care faci-
lities [15], the lack of RDTs and AL at this level of health
care is of concern.
Nearly three-quarters of observed febrile or suspected
malaria patients were tested for malaria infection by
RDT in those facilities that had the capacity to do so, a
statistically significant increase from 40.9% in such faci-
lities pre-implementation of the new NMTP [4]. Over
98% of patients with RDT-confirmed malaria were pre-
scribed an anti-malarial, and in all cases this included
AL, the recommended blood-stage medication for uncom-
plicated malaria infection. Fewer than 20% of malaria
RDT-negative cases were prescribed an anti-malarial, al-
though fewer than 1% of these anti-malarial prescriptions
were AL as were fewer than 1% of anti-malarial prescrip-
tions to presumptively diagnosed patients. Rather, the vast
majority of anti-malarial prescriptions (75%) to RDT-
negative and presumptively diagnosed ‘malaria’ patients
were for the first-line medications of the obsolete treat-
ment protocol (amodiaquine and SP or chloroquine and
SP). Encouragingly, artemether monotherapy were only
prescribed in two cases even though artemether tablets
were available in over 50% of health facilities surveyed.
The prescription of obsolete or non-recommended
anti-malarials to patients diagnosed with malaria, even
when recommended artemisinin combination therapy
are available, has been widely reported in the interna-
tional literature [16]. However, one questions why a
health worker would not prescribe the most effective
anti-malarial medication available (eg, AL) if he/she held
firm to a clinical diagnosis of malaria infection even in
the face of a negative RDT/blood slide. A study from
Tanzania found that local illness labels for febrile illness,
as opposed to biomedical classifications, influenced anti-
malarial prescription [17]. As there is some evidence
that local understanding of malaria may differ to bio-
medical classification in PNG [18,19], then health
worker practice in the study setting may have been simi-
larly influenced. A further influence may have been the
NMTP training programme itself. This programme
strongly promoted a strict test-and-treat with AL stra-
tegy, an unexpected consequence of which may have
been reluctance on the part of health workers to pre-
scribe AL when RDTs were not available or used or
when clinical judgement was used to prescribe anti-
malarials despite a negative RDT result.
Just under 40% of all observed febrile or suspected
malaria patients were prescribed an anti-malarial. This
represents a statistically significant decline in anti-mala-
rial prescription in this population, from a pre-imple-
mentation rate of 96%, and indicates the new NMTP has
affected a substantial change in clinical practice in a
relatively brief period of time. Nevertheless, the majority
of anti-malarial prescriptions made were not consistent
with the new NMTP and it remains questionable as to
whether such a dramatic reduction in anti-malarial pre-
scription is clinically justified. Thus, further investigation
is needed to better understand clinical decision-making
in the absence of malaria diagnostic tests and in the
treatment of malaria RDT/blood slide test negative
cases. The reported findings also suggest that the quality
of treatment counselling is relatively poor, despite em-
phasis in the new NMTP and the associated health
worker training programme [2,20].
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with the international experience. In Zambia, for ex-
ample, health workers diagnosed fewer than 30% of fever
patients with a malaria RDT/blood slide following the
introduction of a treatment protocol similar to that
employed in PNG, even when RDTs/microscopy were
available [8]. Similarly, numerous studies have reported
anti-malarial prescription to between 30 and 50% of
malaria RDT-negative cases [8,21,22], even several years
following the introduction of RDT kits [7]. Seen in this
light, health workers in PNG may be considered to have
made encouraging progress towards full protocol adher-
ence within the first 12 months of implementation. Fac-
tors that may have influenced this outcome included an
independent procurement and supply mechanism estab-
lished specifically for the NMCP, the recruitment of nu-
merous malaria supervisors and laboratory technicians
tasked with supporting the implementation of the
new NMTP at the provincial level, booster training
where required and dedicated funding to support these
initiatives.
Nevertheless, substantial improvement in many areas
is required before a sustained and full implementation of
the new NMTP may be considered achieved. Increased
coverage of RDTs and all recommended first- and
second-line anti-malarial medications is needed, espe-
cially at the aid post level. The ability of the PNG Na-
tional Department of Health’s procurement and supply
mechanism to maintain adequate RDT and anti-malarial
supplies, once the independent system is phased out, re-
mains untested at this stage. In the context of PNG’s de-
clining malaria burden [11], and consequently increasing
proportion of malaria-negative fever cases, supply needs
of both diagnostics and treatment will require constant
re-assessment based on routine surveillance data. Again,
experience from other countries would suggest that sup-
ply stock-out presents a serious threat to protocol imple-
mentation [23] and needs to be closely guarded against.
Further reducing the percentage of malaria RDT/blood
slide negative cases prescribed anti-malarials remains
important. Treating malaria based on RDT diagnosis has
been proven safe in areas with moderate to high endem-
icity of both P. falciparum and P. vivax infections in
PNG [24]. Thus, the local evidence is available to sup-
port the non-prescription of anti-malarials to test nega-
tive cases. The unnecessary prescription of anti-malarials
may accelerate the development of artemisinin resistance
in PNG, especially if artemether monotherapy are pre-
scribed [25], reduces the cost-effectiveness of the test-
and-treat-based malaria case management policy [26]
and may compromise patient wellbeing [27]. Providing
further reassurance to health workers regarding the re-
liability of malaria RDT diagnosis may, therefore, be
required. Similarly, health workers need to be actively
encouraged to prescribe recommended anti-malarials at
all times and in all cases when malaria is diagnosed, even
presumptively. Health workers are likely to require long-
term assistance, ideally via multiple support and super-
visory mechanisms, in order for such substantial and
sustained changes in malaria case management practices
to occur [28].
Advancing understanding of common causes of non-
malaria febrile illness in PNG would usefully inform
health worker practice, although few local studies have
been conducted to date. A recent exception sought to
identify the aetiology of febrile illnesses among patients
(n =136) attending a health centre in Western province,
PNG [29]. An aetiological agent was found in only 13.2%
of these patients; 11% were dengue virus type 1 and
2.2% malaria. An earlier study from Madang province,
PNG, reported a similar rate of dengue infection (8%)
among febrile patients attending local health centres
[30]. These findings suggest dengue is likely to be a
cause of febrile illness in many places across the country,
although it is unlikely to be a major cause of non-
malaria febrile illness and the aetiology and prevalence
of other febrile illnesses remains uncertain. A recent
outbreak of chikungunya in PNG [31] further indicates
that disease profiles are not static and that health wor-
kers need to be adequately equipped to correctly identify
and respond to a wide range of existing and emerging
febrile illnesses.
The reported study was not without limitation. The
health facility survey was conducted during a period of
lower malaria transmission (June-November) in those
provinces with seasonal variation. Thus, the number of
malaria patients presenting to health facilities and the
subsequent pressure on resources (eg, RDT kits, anti-
malarial medication) may have been lower during the
survey period as opposed to peak transmission periods.
It is also possible that health workers may treat patients
differently in low and high transmission seasons depend-
ing on what they perceive the most likely cause of fever
to be. Participating clinicians were aware that they were
being observed and may have altered their clinical prac-
tice accordingly. The expected effect of any such bias
would be towards perceived ‘better’ practice. The sample
excluded private-sector health facilities and, as such,
may not be representative of resource availability and
malaria case management in these settings. However, the
vast majority of health services are provided in a public-
sector context in PNG and the surveyed sample is con-
sidered generally reflective of the range, geographical
spread and quality of public-sector health centres and
aid-posts in the country. The major limitation in terms
of sampling was the lack of clinical case management
data collected from aid-posts. The clinical case manage-
ment data reported in this paper, therefore, should only
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level. Finally, data analysis pertaining to ‘correct’ anti-
malarial prescription was based on medication type and
did not take dosage into account.
Conclusions
The findings presented in this paper suggest that the PNG
National Department of Health (NDoH) has achieved rea-
sonably high coverage of malaria RDTs and AL at the
health centre level and that health workers have made
an encouraging start in implementing the new NMTP.
Nevertheless, many of the medications essential for
full implementation of the NMTP are not widely available,
the ability of the NDoH to maintain supplies has yet to be
tested and further changes in health worker practice are
required. In particular, health workers continue to pre-
scribe obsolete anti-malarials at a higher rate than the
new first- and second-line medications, including 20% of
malaria RDT/blood slide test negative cases. Gaining a
better understanding of the causes of non-malaria fever
may usefully inform health worker practice as would
reassurance as to the reliability of RDTs and the ef-
fectiveness of the new first- and second-line anti-malarial
medications.
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